Letters, Testimony & Comments

June 14, 2002
Dear Majority Leader Daschle:      The Biotechnology Industry Organization (BIO) opposes Senator Brownback's patent amendment to S. 2600, the Terrorism Risk Insurance Act of 2002, now under consideration by the U.S....
June 14, 2002
Dear Senator Hatch:      I read in the Washington Post that Senators are considering a two-year moratorium on somatic cell nuclear transfer (SCNT). On behalf of the Biotechnology Industry Organization (BIO), an...
June 14, 2002
The Honorable Thomas A. Daschle 509 Hart Senate Office Building Washington, DC 20510 Dear Majority Leader Daschle:      The Biotechnology Industry Organization (BIO) opposes Senator Brownback's patent amendment...
June 4, 2002
Letter from HHS Secretary Tommy Thompson
May 15, 2002
Letter to Senator Ron Wyden (May 15, 2002).
May 9, 2002
Good morning, ladies and gentlemen. My name is Carl Feldbaum, and I'm here today to talk about the major political and regulatory forces shaping the biotechnology industry. The impact of those forces is large. Policy matters for this young and...
May 7, 2002
Dan Eramian, Vice President, Communications, Biotechnology Industry Organization (BIO) I don't know a better way to start a fight than to bring up politics or religion. Of course, my organization like other trade groups in Washington,...
May 6, 2002
Under Secretary of Commerce for Intellectual Property and Director of the USPTO on Patent Harmonization
April 29, 2002
Ladies and gentlemen, good afternoon. I'm Carl Feldbaum, president of the Biotechnology Industry Organization, and I'm here today to report on the state of our industry, which is, from a big picture perspective, excellent. Biotechnology...
April 25, 2002
Robinsue Frohboese, Ph.D. Acting Director, Office for Civil Rights U.S. Department of Health and Human Services Attention: Privacy 2, Room 425A Hubert H. Humphrey Building 200 Independence Avenue, S.W. Washington, D.C. 20201   Re:...
April 23, 2002
Good morning, Mr. Chairman and Members of the Committee. My name is Dr. Charles Johnson. I am Associate Director of Specialty Biotherapeutics at Genentech, Inc., a leading biotechnology company headquartered in South San Francisco, California. I...
April 23, 2002
Good morning, Mr. Chairman and Members of the Committee. My name is Dr. Charles Johnson. I am Associate Director of Specialty Biotherapeutics at Genentech, Inc., a leading biotechnology company headquartered in South San Francisco, California. I...
April 11, 2002
Summary The biotechnology industry is the most research and development intensive and capital-focused industry in the world. The United States currently leads the world in the area of biotechnology because U.S. patent laws and legislation such as...